IP Library › Granted Patent US 8,084,591
Granted Patent B2
US 8,084,591 · App. 11/423,622 · Granted Dec 27, 2011

Factor VII or VIIA-like molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,591
App. No.
11/423,622
Granted
Dec 27, 2011
Kind
B2
Abstract

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Claims (4)

1. An isolated nucleotide sequence encoding a FVII or FVIIa polypeptide having clotting activity, which differs from the wild-type FVII or FVIIa sequence shown in SEQ ID NO: 1 in that an in vivo N-glycosylation site has been introduced by an amino acid residue substitution selected from the group consisting of K143N+N145S/T, R290N+A292S/T, D289N+G291S/T, R315N+V317S/T, S314N+K316S/T, K316N+G318S/T, K341N+D343S/T, R396N+G398S/T, P404N+P406S/T, and combinations thereof.

2. An expression vector comprising the nucleotide sequence of claim 1 .

3. An isolated host cell comprising the nucleotide sequence according to claim 1 or an expression vector according to claim 2 .

4. The host cell according to claim 3 , wherein the host cell is a gammacarboxylating cell capable of in vivo glycosylation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2008
From: MAXYGEN HOLDINGS LTD.
To: BAYER HEALTHCARE LLC
Reel/Frame 021450/0225 →